Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma
Shailendra Singh(University of Leicester), David G. Lambert(Griffith University), Renzo Guerrini(Meyer Children's Hospital), Raffaele De Palma(University of Campania "Luigi Vanvitelli"), Girolamo Calò(University of Padua), Giuseppe Spaziano(University of Campania "Luigi Vanvitelli"), Nikol Sullo(Institute for Experimental Endocrinology and Oncology), Ruth Saunders(University of Leicester), Lucy Woodman(University of Leicester), Vijay Mistry(University of Leicester), Christopher E. Brightling(NIHR Leicester Biomedical Research Centre), J. McDonald, Rachid Berair(University of Leicester), Bruno D’Agostino(University of Naples - L'Orientale), Francesco Rossi(Azienda Ospedaliero-Universitaria Careggi), Maria Matteis(University of Padua), Konrad Urbanek(San Salvatore Hospital), Mitesh Pancholi(University of Leicester), Antonella De Angelis(University of Campania "Luigi Vanvitelli")
Cited by 28
Related Papers
The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission1
|Epilepsia|2010|1.7k
Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks
|Nature Genetics|2017|591
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Pharmacology of nociceptin and its receptor: a novel therapeutic target
|British Journal of Pharmacology|2000|432